ArticleJournal of translational medicine2013
Melanoma risk loci as determinants of melanoma recurrence and survival.
Article in Journal of translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Pooled it
- Aldehyde reductase as potential measurement for retinitis pigmentosa: A two-sample Mendelian randomization (MR) study.Medicine · 2026Article
- Machine Learning-Based Prognostic Signature in Breast Cancer: Regulatory T Cells, Stemness, and Deep Learning for Synergistic Drug Discovery.International journal of molecular sciences · 2025Article
- Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.BMC medical genomics · 2023Article
- A pan‑cancer analysis of RCC2 and its interaction with HMGA2 protein in an in vitro model of colorectal cancer cells.Experimental and therapeutic medicine · 2022Article
- Association of TYR SNP rs1042602 with Melanoma Risk and Prognosis.Life (Basel, Switzerland) · 2022Article
- Analysis of prognostic and therapeutic values of drug resistance-related genes in the lung cancer microenvironment.Translational cancer research · 2022Article
- A genome-wide association study of germline variation and melanoma prognosis.Frontiers in oncology · 2022Article
- Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle.Oncology reviews · 2021Article
- Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.Scientific reports · 2020Article
- Regulator of Chromosome Condensation 2 Modulates Cell Cycle Progression, Tumorigenesis, and Therapeutic Resistance.Frontiers in molecular biosciences · 2020Review
- Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM).Scientific reports · 2019Article
- RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.BMC cancer · 2018Article
- Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival.PloS one · 2017Article
- The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Germline determinants of clinical outcome of cutaneous melanoma.Pigment cell & melanoma research · 2016Review
- Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates.Bioinformatics (Oxford, England) · 2016Article
- Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis.BMC cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSteadily high melanoma mortality rates urge for the availability of novel biomarkers with a more personalized ability to predict melanoma clinical outcomes. Germline risk variants are promising candidates for this purpose; however, their prognostic potential in melanoma has never been systematically tested.
methodsWe examined the effect of 108 melanoma susceptibility single nucleotide polymorphisms (SNPs), associated in recent GWAS with melanoma and melanoma-related phenotypes, on recurrence-free survival (RFS) and overall survival (OS), in 891 prospectively accrued melanoma patients. Cox proportional hazards models (Cox PH) were used to test the associations between 108 melanoma risk SNPs and RFS and OS adjusted by age at diagnosis, gender, tumor stage, histological subtype and other primary tumor characteristics.
resultsWe identified significant associations for rs7538876 (RCC2) with RFS (HR=1.48, 95% CI=1.20-1.83, p=0.0005) and rs9960018 (DLGAP1) with both RFS and OS (HR=1.43, 95% CI=1.07-1.91, p=0.01, HR=1.52, 95% CI=1.09-2.12, p=0.01, respectively) using multivariable Cox PH models. In addition, we developed a logistic regression model that incorporates rs7538876, rs9960018, primary tumor histological type and stage at diagnosis that has an improved discriminatory ability to classify 3-year recurrence (AUC=82%) compared to histological type and stage alone (AUC=78%).
conclusionsWe identified associations between melanoma risk variants and melanoma outcomes. The significant associations observed for rs7538876 and rs9960018 suggest a biological implication of these loci in melanoma progression. The observed predictive patterns of associated variants with clinical end-points suggest for the first time the potential for utilization of genetic risk markers in melanoma prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.